MYC and lymphoma: In the Eu-MYC model, treating lymphoma-prone mice with DFMO extended survival [4] to a similar extent as genetic crosses into the RPL24+/− background [39] or a dominant-negative 4EBP1 mutant background [42], consistent with the notion that the major mechanism downstream of DFMO is disruption of protein translation.